Roseland, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it has closed its previously announced private placement for the purchase and sale of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares of common stock at a purchase price of $5.57 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $5.50 per share and are exercisable immediately upon issuance. The series A warrants expire five and one-half years from the date of issuance and short-term series B warrants expire twenty-four months from the date of issuance.

Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) --  Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares of common stock at a purchase price of $5.57 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $5.50 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire twenty-four months from the date of issuance. The private placement is expected to close on or about March 15, 2024, subject to the satisfaction of customary closing conditions.

Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, “Ultiself,” in order to facilitate the development of its tech for Gaxos Health.

Roseland, NJ, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that its health and wellness division, Gaxos Health, has formed a medical advisory board for providing invaluable insight into product development and creating strategic opportunities. The Company has appointed Dr. Nate Lebowitz, M.D. as the Chairman of the Advisory Board.

Roseland, NJ, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that its gaming division, Gaxos Gaming, will launch an artificial intelligence (AI) solution for game developers and studios.

Roseland, NJ, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications various sectors, today announced a significant strategic expansion with Gaxos Health, a division dedicated to revolutionizing personal health and wellness.